Mega menu

Home
Product regulation
Product regulation

Understand your obligations and access industry Guidance and other information about the products we regulate.
Safety and shortages
Safety and shortages

Access information about product recalls, shortages and other alerts, and learn how we manage safety.
Resources and guidance
Resources and guidance

Get information to help you understand our work, regulations and industry obligations.
Business services
Business services

Access our systems to submit applications, manage forms, make payments and communicate securely.

AstraZeneca Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

ARTG (111)
Cancellation by sponsor (70)
Prescription medicine registration (60)
Australian public assessment report (AusPar) (48)
Designation or determination (24)
Prescription medicine decision summary (12)
Prescription medicine evaluation (10)
Section 14, TGO91 consent (1)

Date

2026 (15)
2025 (32)
2024 (28)
2023 (30)
2022 (45)
2021 (25)
2020 (16)
2019 (20)
2018 (19)
2017 (14)
2016 (11)
2015 (14)
2014 (13)
2013 (6)
2012 (3)
2011 (5)
2010 (4)
2008 (3)
2006 (5)
2004 (2)
2003 (5)
2002 (2)
2001 (2)
1997 (2)
1996 (3)
1991 (12)

Search

Sponsor content

336 result(s) found, displaying 231 to 240

SYNAGIS palivizumab (rmc) 50 mg / 0.5 mL solution for injection vial (231133)

24 September 2015

ARTG

Australian Register of Therapeutic Goods (ARTG) information for SYNAGIS palivizumab (rmc) 50 mg / 0.5 mL solution for injection vial.
IMFINZI (AstraZeneca Pty Ltd)

22 October 2018

Prescription medicine registration

Active ingredients: durvalumab.
IMFINZI (AstraZeneca Pty Ltd)

2 October 2018

Prescription medicine registration

Active ingredients: durvalumab (rch).
BEVESPI AEROSPHERE (AstraZeneca Pty Ltd)

27 September 2018

Prescription medicine registration

Active ingredients: glycopyrronium bromide (glycopyrrolate); formoterol (eformoterol) fumarate dihydrate.
Notice for olaparib (AstraZeneca Pty Ltd)

27 September 2018

Designation or determination

Priority review
LYNPARZA (AstraZeneca Pty Ltd)

1 August 2018

Prescription medicine registration

Active ingredients: olaparib.
BYDUREON (AstraZeneca Pty Ltd)

25 July 2018

Prescription medicine registration

Active ingredients: exenatide.
BYDUREON (AstraZeneca Pty Ltd)

25 July 2018

Prescription medicine registration

Active ingredients: exenatide.
TAGRISSO (AstraZeneca Pty Ltd)

3 July 2018

Prescription medicine registration

Active ingredients: osimertinib mesilate.
LYNPARZA (AstraZeneca Pty Ltd)

18 May 2018

Prescription medicine registration

Active ingredients: olaparib.

Pages

First page
Previous page
…
Page 20
Page 21
Page 22
Page 23
Current page 24
Page 25
Page 26
Page 27
Page 28
…
Next page
Last page

Using our website

Accessibility
Privacy
Security
Disclaimer
Copyright
Freedom of information
Acronyms and glossary terms

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Email subscriptions
Contact us
Facebook
(formerly Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health, Disability and Ageing acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.